Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.
(Stock Exchange Code: 4516) Date of issue: June 10, 2024
To Shareholders with Voting Rights:
Toru Nakai
Representative Director, President
Nippon Shinyaku Co., Ltd.
14, Nishinosho-Monguchi-cho,
Kisshoin, Minami-ku, Kyoto, Japan
NOTICE OF
THE 161ST ANNUAL GENERAL MEETING OF SHAREHOLDERS
Dear Shareholders:
We would like to express our appreciation for your continued support and patronage.
You are cordially informed of the 161st Annual General Meeting of Shareholders of Nippon Shinyaku Co., Ltd. (the "Company"). The meeting will be held for the purposes as described below.
In convening this General Meeting of Shareholders, the Company has taken measures for electronic provision and has posted the matters subject to the measures for electronic provision as "NOTICE OF THE 161ST ANNUAL GENERAL MEETING OF SHAREHOLDERS" on the Company's website on the Internet indicated below.
The Company's website: https://www.nippon-shinyaku.co.jp/english/ir/ir_stock/smeeting.php
Matters subject to the measures for electronic provision are also posted on the website of the Tokyo Stock Exchange (TSE) indicated below, in addition to the Company's website. When you access the TSE website, search for the Company by entering "Nippon Shinyaku" in the "Issue name (company name)" field or "4516" in the "Code" field. On the search results page, select "Basic information" and then "Documents for public inspection/PR information," and click "Notice of General Shareholders Meeting/Informational Materials for a General Shareholders Meeting" under "Filed information available for public inspection" to review the information.
TSE website (TSE Listed Company Search) https://www2.jpx.co.jp/tseHpFront/JJK020010Action.do?Show=Show
If you do not attend the meeting, you can exercise your voting rights either by postcard or via the Internet, so please review the attached Reference Documents for the General Meeting of Shareholders and indicate your vote for or against the proposal on the enclosed Voting Rights Exercise Form and return it by 5:30 p.m. on Wednesday, June 26, 2024, Japan time, or access the website for exercising voting rights (https://evote.tr.mufg.jp/) and input your vote for or against the proposal.
- Date and Time:
- Place:
Thursday, June 27, 2024 at 10:00 a.m. Japan time
Head Office Auditorium of Nippon Shinyaku Co., Ltd. located at 14, Nishinosho-Monguchi-cho, Kisshoin, Minami-ku, Kyoto, Japan
(When attending the meeting, please submit the enclosed Voting Rights Exercise Form at the reception desk.)
- 1 -
3. Meeting Agenda:
Matters to be reported: 1.The Business Report, Consolidated Financial Statements for the Company's 161st
Fiscal Year (April 1, 2023 - March 31, 2024) and results of audits by the | |
Accounting Auditor and the Audit & Supervisory Board of the Consolidated | |
Financial Statements | |
2.Non-consolidated Financial Statements for the Company's 161st Fiscal Year | |
Proposals to be resolved: | (April 1, 2023 - March 31, 2024) |
Appropriation of Surplus | |
Proposal 1: | |
Proposal 2: | Election of 12 Directors |
Proposal 3: | Election of 2 Audit & Supervisory Board Members |
Proposal 4: | Introduction of a Restricted Stock Remuneration Plan for Directors (Excluding |
Outside Directors) |
4. Matters Determined in Regard to the Convocation
・If voting rights are exercised both in writing and via the Internet, the vote submitted via the Internet shall be considered the valid exercise of voting rights. If voting rights are exercised multiple times via the Internet, the final vote submitted shall be considered the valid exercise of voting rights.
・If there is no indication of a vote for against a specific proposal on the Voting Rights Exercise Form, it shall be deemed as an indication of approval to that proposal.
・Pursuant to the provisions of relevant laws and regulations and Article 16 of the Company's Articles of Incorporation, the following matters are posted on the Company's website and the TSE website, thus they are not provided in the paper-based documents delivered to shareholders. In addition, the Audit & Supervisory Board Members and the Accounting Auditor have audited the documents to be audited, including the following matters.
[Business Report]
The following matters regarding the current status of the corporate group: "Issues to be addressed," "Trends in assets and profit and loss," "Main businesses," "Main offices and plants," "Status of employees," matters concerning the Company's shares, the following matters concerning the Company's officers: "Matters concerning outside officers," matters concerning the Accounting Auditor, matters concerning the Company's structure and policies
[Consolidated Financial Statements]
Consolidated Statement of Changes in Net Assets and Notes to the Consolidated Financial Statements [Non-consolidated Financial Statements]
Balance Sheet, Income Statement, Non-consolidated Statements of Changes in Net Assets, and Notes to the Non-Consolidated Financial Statements
[Audit Reports]
Audit Report of the Accounting Auditor on the Consolidated Financial Statements, Audit Report of the Accounting Auditor, and Audit Report of the Audit & Supervisory Board Members
≪Note≫
Should the matters subject to the measures for electronic provision require revisions, the revisions will be posted on the relevant websites on which the matters are posted.
- 2 -
Reference Documents for the General Meeting of Shareholders
Proposals and References
Proposal 1: Appropriation of Surplus
Our policy on returning profits appropriately to shareholders is maintaining stable dividends while taking into consideration the dividend on equity (DOE) ratio.
In accordance with our basic policy of maximizing corporate value, we will work to enhance our R&D pipeline by bolstering our research and development structure, and we will strive to further strengthen our management base while balancing investment and return of profits in order to develop a corporate structure capable of withstanding increasingly intense competition.
Based on the above policy, the year-end dividend for the fiscal year is proposed as follows:
- Type of Dividend: Cash
-
Items relating to the allocation of dividend assets to shareholders and its total amount: JPY62 per share of common stock of the Company
Total amount: JPY4,175,870,996
Together with the interim dividend of JPY62 per share, the annual dividend will be JPY124 per share. - Effective Date of Distribution of Retained Earnings:
Friday, June 28, 2024
- 3 -
Proposal 2: Election of 12 Directors
The terms of office of all 12 Directors, including 4 Outside Directors, will expire at the conclusion of this year's Annual General Meeting of Shareholders. Accordingly, the election of 12 Directors, including 4 Outside Directors, is proposed.
The candidates are as follows:
Current positions and | Tenure | Attendance | Significant concurrent | ||||||||
No. | Name | at Board of | |||||||||
responsibilities at the | of | Directors | positions | ||||||||
Company | office | ||||||||||
meetings | |||||||||||
Representative Director, | 100% | Chairman, | |||||||||
Kyoto Employers' Association | |||||||||||
1 | Reappointment | Shigenobu Maekawa | 19 | ||||||||
Chairman | (14/14) | Outside Director, | |||||||||
KYOCERA Corporation | |||||||||||
Representative Director, | 100% | ||||||||||
2 | Reappointment | Toru Nakai | 5 | ||||||||
President | (14/14) | ||||||||||
Managing Director, | 100% | ||||||||||
3 | Reappointment | Shouzou Sano | 9 | ||||||||
Sales and Marketing | (14/14) | ||||||||||
Director, | |||||||||||
Personnel, General Affairs, | 100% | ||||||||||
4 | Reappointment | Takashi Takaya | Risk Management, | 6 | |||||||
(14/14) | |||||||||||
Compliance | |||||||||||
& Digital Transformation | |||||||||||
Director, | 100% | ||||||||||
5 | Reappointment | Takanori Edamitsu | Business Management, | 6 | |||||||
(14/14) | |||||||||||
& Sustainability | |||||||||||
Director, | 100% | ||||||||||
6 | Reappointment | Kazuchika Takagaki | 3 | ||||||||
Research & Development | (14/14) | ||||||||||
Director, | 100% | ||||||||||
7 | Reappointment | Hitoshi Ishizawa | 3 | ||||||||
Functional Food | (14/14) | ||||||||||
Director, | 100% | ||||||||||
8 | Reappointment | Hitomi Kimura | Resource Procurement, | 3 | |||||||
(14/14) | |||||||||||
Production & Assurance | |||||||||||
Joint Owner, | |||||||||||
Hanamizuki Law Office | |||||||||||
Member of the Board, | |||||||||||
Reappointment | 100% | ||||||||||
9 | Miyuki Sakurai | Outside Director | 7 | NIPPON SHOKUBAI CO., | |||||||
Outside | |||||||||||
(14/14) | LTD. | ||||||||||
Independent | |||||||||||
Outside Auditor, | |||||||||||
MBS MEDIA HOLDINGS, | |||||||||||
INC. | |||||||||||
Part-time physician, | |||||||||||
Reappointment | 100% | ||||||||||
Department of Maternal | |||||||||||
10 | Outside | Yoshinao Wada | Outside Director | 5 | |||||||
(14/14) | Medicine, Osaka Women's | ||||||||||
Independent | |||||||||||
and Children's Hospital | |||||||||||
Representative Partner, | |||||||||||
Amanda Life Consulting LLC. | |||||||||||
Reappointment | 100% | Outside Director, Panasonic | |||||||||
11 | Outside | Yukari Kobayashi | Outside Director | 3 | Connect Co., Ltd. | ||||||
(14/14) | |||||||||||
Independent | Outside Director, | ||||||||||
Bridgestone Corporation | |||||||||||
CEO, JC1 LLC | |||||||||||
Reappointment | 100% | ||||||||||
12 | Outside | Mayumi Nishi | Outside Director | 1 | |||||||
(11/11) | |||||||||||
Independent | |||||||||||
- 4 -
No. | Name | Past experience, positions and responsibilities at the Company | Number of | |||
shares of the | ||||||
(Date of birth) | and significant concurrent positions | |||||
Company held | ||||||
April 1976 | Joined the Company | |||||
March 1992 | Transfer to Japan Federation of Employers' Associations | |||||
April 2002 | Department Manager, Corporate Planning Department, | |||||
Corporate Strategy Office | ||||||
April 2004 | Corporate Officer | |||||
June 2005 | Director | |||||
June 2005 | Corporate Planning, Finance & Accounting, and Information | |||||
system, and Department Manager, Corporate Planning | ||||||
Department | ||||||
June 2006 | Managing Director | |||||
Reappointment | April 2007 | General Manager, Corporate Planning, Finance & Accounting, | ||||
Shigenobu Maekawa | and Information system | |||||
June 2007 | Representative Director, President | |||||
1 | (January 18, 1953) | June 2021 | Representative Director, Chairman (current position) | 53,400 | ||
Tenure of office: | June 2023 | Outside Director, KYOCERA Corporation (current position) | ||||
[Significant concurrent positions] | ||||||
19 years | ||||||
Chairman, Kyoto Employers' Association | ||||||
Attendance at Board | Outside Director, KYOCERA Corporation | |||||
of Directors meetings: | [Reasons for the nomination for Director] | |||||
100% | After joining the Company in 1976, Mr. Shigenobu Maekawa assumed positions | |||||
(14/14) | ||||||
including Department Manager, Corporate Planning Department from 2002, | ||||||
Director in charge of Corporate Planning, Finance & Accounting, and Information | ||||||
System from 2005, Managing Director from 2006, President from 2007, and | ||||||
Chairman (current position) from 2021. The Company nominates him for Director | ||||||
as he has a wealth of experience and broad insight as a business manager and he | ||||||
appropriately manages the Board of Directors by chairing meetings as a | ||||||
Representative Director. | ||||||
April 1995 | Joined the Company | |||||
April 2016 | Department Manager, Business Planning Department | |||||
April 2018 | Acting General Manager, Corporate Planning (NS Pharma, Inc.) | |||||
April 2019 | General Manager, Global Business Division, Attached to Global | |||||
Business Division (NS Pharma, Inc.) | ||||||
June 2019 | Director | |||||
June 2019 | General Manager, Global Business; Head of Global Business | |||||
Division | ||||||
June 2021 | Representative Director, President (current position) | |||||
2 | Reappointment | 11,100 | ||||
Toru Nakai | [Reasons for the nomination for Director] | |||||
After joining the Company in 1995, Mr. Toru Nakai assumed positions including | ||||||
(December 23, 1971) | ||||||
Department Manager, Business Planning Department from 2016. Further, in 2018, | ||||||
Tenure of office: | he was transferred to U.S. subsidiary NS Pharma, Inc. (General Director, Corporate | |||||
Planning of U.S. branch). In 2019, he was General Manager, Global Business | ||||||
5 years | ||||||
Division and later became Director in charge of Global Business. He assumed the | ||||||
Attendance at Board | position of President (current position) from 2021. The Company nominates him for | |||||
Director as he has a wealth of experience in global business and broad insight into | ||||||
of Directors meetings: | such field and he has been fully demonstrating leadership as a member of the | |||||
100% | management team of the Company. | |||||
(14/14) | ||||||
- 5 -
No. | Name | Past experience, positions and responsibilities at the Company | Number of | |||
shares of the | ||||||
(Date of birth) | and significant concurrent positions | |||||
Company held | ||||||
April 1984 | Joined the Company | |||||
April 2008 | Department Manager, Saitama Branch Office, Sales and | |||||
Marketing | ||||||
April 2010 | Corporate Officer; Department Manager, Osaka Branch Office, | |||||
Sales Promotion Division, Sales and Marketing | ||||||
April 2013 | Corporate Officer; Head of Tokyo Area Division, Sales and | |||||
Marketing | ||||||
April 2015 | Corporate Officer; Head of Sales and Marketing | |||||
June 2015 | Director | |||||
June 2015 | General Manager, Sales and Marketing; Head of Sales and | |||||
Reappointment | ||||||
Marketing Division (current position) | ||||||
3 | 7,200 | |||||
Shouzou Sano | June 2019 | Managing Director (current position) | ||||
(July 14, 1960) | [Reasons for the nomination for Director] | |||||
Tenure of office: | After joining the Company in 1984, Mr. Shouzou Sano assumed positions including | |||||
Department Manager of Saitama Branch Office from 2008, Department Manager of | ||||||
9 years | ||||||
Osaka Branch Office from 2010, Head of Tokyo Area Division from 2013, Director | ||||||
Attendance at Board | in charge of Sales and Marketing (current position) from 2015, and Managing | |||||
of Directors | Director (current position) from 2019. The Company nominates him for Director as | |||||
he has a wealth of business experience in sales division of medical products and | ||||||
meetings: | ||||||
broad insight into such field. | ||||||
100% | ||||||
(14/14) | ||||||
April 1984 | Joined the Company | |||||
April 2005 | Department Manager, Marketing Department, Sales and | |||||
Marketing | ||||||
April 2009 | Department Manager, Marketing Department, Sales and | |||||
Marketing Planning Division, Sales and Marketing | ||||||
April 2010 | Department Manager, Marketing and Planning Department, | |||||
Sales and Marketing Planning Division, Sales and Marketing | ||||||
April 2011 | Head of Sales and Marketing Planning Division, Sales and | |||||
Marketing | ||||||
April 2012 | Corporate Officer; Head of Sales and Marketing Planning | |||||
Reappointment | ||||||
Division, Sales and Marketing | ||||||
Takashi Takaya | June 2018 | Director (current position) | ||||
June 2018 | General Manager, Administration | |||||
(November 13, 1960) | ||||||
4 | April 2022 | General Manager, Personnel, General Affairs, Risk | 5,300 | |||
Management, Compliance & Digital Transformation (current | ||||||
Tenure of office: | position) | |||||
6 years | [Reasons for the nomination for Director] | |||||
Attendance at Board | After joining the Company in 1984, Mr. Takashi Takaya assumed positions | |||||
including Manager, Business Planning Section, Tokyo Branch Office from 1999, | ||||||
of Directors meetings: | Section Manager, Corporate Strategy Department from 2001, Manager, Planning | |||||
100% | Section, Marketing and Planning Department from 2003, Department Manager, | |||||
(14/14) | Marketing Department from 2005, Department Manager, Marketing and Planning | |||||
Department from 2010, Head of Sales and Marketing Planning Division from 2011, | ||||||
and Director in charge of Administration from 2018. He assumed the new position | ||||||
of Director in charge of Personnel, General Affairs, Risk Management, Compliance | ||||||
& Digital Transformation (current position) from 2022. The Company nominates | ||||||
him for Director as he has a wealth of business experience and broad insight into | ||||||
such field. |
- 6 -
No. | Name | Past experience, positions and responsibilities at the Company | Number of | |||
shares of the | ||||||
(Date of birth) | and significant concurrent positions | |||||
Company held | ||||||
April 1989 | Joined the Company | |||||
August 2011 | Department Manager, Corporate Planning Department | |||||
April 2013 | Corporate Officer; Department Manager, Corporate Planning | |||||
Department | ||||||
June 2018 | Director (current position) | |||||
June 2018 | General Manager, Business Management | |||||
April 2022 | General Manager, Business Management & Sustainability | |||||
(current position) | ||||||
Reappointment | ||||||
5 | Takanori Edamitsu | 4,800 | ||||
[Reasons for the nomination for Director] | ||||||
(August 8, 1963) | ||||||
After joining the Company in 1989, Mr. Takanori Edamitsu assumed positions | ||||||
Tenure of office: | including Manager, Corporate Planning Section, Corporate Planning Department | |||||
from 2005, Department Manager, Corporate Planning Department from 2011, and | ||||||
6 years | Director in charge of Business Management from 2018. He assumed the new | |||||
position of Director in charge of Business Management & Sustainability (current | ||||||
Attendance at Board | position) from 2022. The Company nominates him for Director as he has a wealth | |||||
of experience in corporate planning and broad insight into such field. | ||||||
of Directors meetings: | ||||||
100% | ||||||
(14/14) | ||||||
April 1986 | Joined the Company | |||||
June 2014 | Department Manager, Discovery Research Laboratories in | |||||
Tsukuba, Discovery Research Labs., Research & Development | ||||||
June 2016 | Department Manager, Discovery Research Labs., Research & | |||||
Development | ||||||
April 2017 | Corporate Officer; Department Manager, Discovery Research | |||||
Labs., Research & Development | ||||||
June 2021 | Director (current position) | |||||
June 2021 | General Manager, Research & Development; Head of Research | |||||
& Development Division (current position) | ||||||
Reappointment | ||||||
6 | Kazuchika Takagaki | 3,900 | ||||
(November 15, 1961) | [Reasons for the nomination for Director] | |||||
Tenure of office: | After joining the Company in 1986, Mr. Kazuchika Takagaki assumed positions | |||||
including Department Manager, Discovery Research Laboratories in Tsukuba from | ||||||
3 years | ||||||
2014, Department Manager, Discovery Research Labs. from 2016, and Director in | ||||||
charge of Research & Development (current position) from 2021. The Company | ||||||
Attendance at Board | nominates him for Director as he has a wealth of business experience in research and | |||||
of Directors meetings: | development and broad insight into such field. | |||||
100% | ||||||
(14/14) | ||||||
- 7 -
No. | Name | Past experience, positions and responsibilities at the Company | Number of | |||
shares of the | ||||||
(Date of birth) | and significant concurrent positions | |||||
Company held | ||||||
April 1985 | Joined the Company | |||||
April 2013 | Department Manager, Kita-Kanto Branch Office, Northern | |||||
Japan Division, Sales and Marketing | ||||||
April 2014 | Department Manager, Chugoku Branch Office, Western Japan | |||||
Division, Sales and Marketing | ||||||
April 2015 | Department Manager, Tokyo Branch Office, Eastern Japan | |||||
Division, Sales and Marketing | ||||||
April 2017 | Department Manager, Osaka Branch Office, Sales and | |||||
Marketing | ||||||
April 2018 | Corporate Officer; Department Manager, Osaka Branch Office, | |||||
Reappointment | Sales and Marketing | |||||
April 2021 | Corporate Officer; Department Manager, Kansai Branch Office, | |||||
7 | Hitoshi Ishizawa | Sales and Marketing | 5,100 | |||
June 2021 | Director (current position) | |||||
(September 18, 1961) | ||||||
June 2021 | General Manager, Functional Food; Head of Functional Food | |||||
Tenure of office: | Division (current position) | |||||
3 years | [Reasons for the nomination for Director] | |||||
After joining the Company in 1985, Mr. Hitoshi Ishizawa assumed positions | ||||||
Attendance at Board | including Department Manager of Kita-Kanto Branch Office from 2013, Department | |||||
Manager of Chugoku Branch Office from 2014, Department Manager of Tokyo | ||||||
of Directors meetings: | ||||||
100% | Branch Office from 2015, and Department Manager of Osaka Branch Office from | |||||
2017. In 2021, he was Department Manager of Kansai Branch Office and later | ||||||
(14/14) | ||||||
became Director in charge of Functional Food (current position). The Company | ||||||
nominates him for Director based on a belief that he can effectively utilize his wealth | ||||||
of business experience in sales division of medical products and broad insight into | ||||||
functional food division. | ||||||
April 1984 | Joined the Company | |||||
April 2015 | Department Manager, Regulatory Affairs Department, | |||||
Regulatory Affairs, Safety Management and Quality Assurance | ||||||
Division | ||||||
April 2020 | Head of Regulatory Affairs, Safety Management and Quality | |||||
Assurance Division (Marketing Supervisor-General) | ||||||
April 2021 | Corporate Officer; Head of Regulatory Affairs, Safety | |||||
Management and Quality Assurance Division (Marketing | ||||||
Supervisor-General) | ||||||
June 2021 | Director (current position) | |||||
Reappointment | ||||||
8 | June 2021 | General Manager, Resource Procurement, Production & | 1,900 | |||
Assurance (current position) | ||||||
Hitomi Kimura | ||||||
(September 2, 1961) | [Reasons for the nomination for Director] | |||||
Tenure of office: | After joining the Company in 1984, Ms. Hitomi Kimura assumed positions including | |||||
Department | Manager, Regulatory Affairs Department from 2015 and Head of | |||||
3 years | ||||||
Regulatory Affairs, Safety Management and Quality Assurance Division (Marketing | ||||||
Attendance at Board | Supervisor-General) from 2020, and Director in charge of Resource Procurement, | |||||
Production & Assurance (current position) from 2021. The Company nominates her | ||||||
of Directors meetings: | for Director as she has a wealth of business experience in supply chain and safety | |||||
100% | quality assurance and broad insight into such field. | |||||
(14/14) |
- 8 -
No. | Name | Past experience, positions and responsibilities at the Company | Number of | |||||||
shares of the | ||||||||||
(Date of birth) | and significant concurrent positions | |||||||||
Company held | ||||||||||
April 1992 | Completed training program at Legal Training and Research | |||||||||
Institute of Japan | ||||||||||
April 1992 | Registered with Osaka Bar Association | |||||||||
April 1992 | Joined Nishimura Law and Accounting Office | |||||||||
May 2003 | Joint Owner, Hanamizuki Law Office (current position) | |||||||||
March 2015 | Auditor, Nissay Life Foundation (current position) | |||||||||
April 2016 | Auditor, Osaka University (current position) | |||||||||
June 2017 | Director, the Company (current position) | |||||||||
June 2020 | Member of the Board, NIPPON SHOKUBAI CO., LTD. (current | |||||||||
position) | ||||||||||
June 2022 | Outside Audit & Supervisory Board Member, MBS MEDIA | |||||||||
Reappointment | ||||||||||
9 | HOLDINGS, INC. (current position) | 800 | ||||||||
Outside | ||||||||||
Independent | [Significant concurrent positions] | |||||||||
Miyuki Sakurai | Joint Owner, Hanamizuki Law Office | |||||||||
Member of the Board, NIPPON SHOKUBAI CO., LTD. | ||||||||||
(December 15, 1964) | ||||||||||
Tenure of office: | Outside Audit & Supervisory Board Member, MBS MEDIA HOLDINGS, INC. | |||||||||
7 years | ||||||||||
Attendance at Board | [Reasons for the nomination for Outside Director and outline of expected roles] | |||||||||
The Company nominates Ms. Miyuki Sakurai for Outside Director, as she is offering | ||||||||||
of Directors meetings: | ||||||||||
advice to the management of the Company from a practical perspective based on her | ||||||||||
100% | expertise and insight from an independent standpoint as a lawyer. | |||||||||
(14/14) | ||||||||||
- 9 -
Name | Past experience, positions and responsibilities at the Company | Number of | ||||||||
No. | shares of the | |||||||||
(Date of birth) | and significant concurrent positions | |||||||||
Company held | ||||||||||
July 1975 | Joined Osaka University Hospital | |||||||||
November 1981 | Department of Maternal Medicine, Osaka Medical Center for | |||||||||
Maternal and Child Health | ||||||||||
October 1989 | Obtained the degree of Doctor of Medicine (Osaka University) | |||||||||
April 1991 | Department Manager, Department of Molecular Medicine, | |||||||||
Research Institute, Osaka Medical Center for Maternal and Child | ||||||||||
Health | ||||||||||
April 1998 | Director, Research Institute, Osaka Medical Center for Maternal | |||||||||
and Child Health | ||||||||||
April 2011 | Department Manager, Department of Maternal Medicine; | |||||||||
Reappointment | Director, Research Institute; Osaka Medical Center for Maternal | |||||||||
Outside | and Child Health | |||||||||
Independent | April 2014 | Chief Department Manager, Department of Maternal Medicine; | ||||||||
Yoshinao Wada | Director, Research Institute; Osaka Medical Center for Maternal | |||||||||
10 | and Child Health | 300 | ||||||||
(December 25, 1950) | April 2016 | Part-time physician, Department of Maternal Medicine, Osaka | ||||||||
Tenure of office: | Medical Center for Maternal and Child Health | |||||||||
April 2017 | Part-time physician, Department of Maternal Medicine, Osaka | |||||||||
5 years | Women's and Children's Hospital (current position) | |||||||||
Attendance at Board | April 2018 | Visiting Professor, Yokohama City University | ||||||||
June 2019 | Director, the Company (current position) | |||||||||
of Directors meetings: | ||||||||||
100% | [Significant concurrent positions] | |||||||||
(14/14) | Part-time physician, Department of Maternal Medicine, Osaka Women's and | |||||||||
Children's Hospital | ||||||||||
[Reasons for the nomination for Outside Director and outline of expected roles] | ||||||||||
The Company nominates Dr. Yoshinao Wada for Outside Director, as he is offering | ||||||||||
advice to the management of the Company from a practical perspective based on his | ||||||||||
expertise and insight from an independent standpoint as a physician. |
- 10 -
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Nippon Shinyaku Co. Ltd. published this content on 04 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 June 2024 00:10:07 UTC.